PSNL Personalis, Inc.
USHealthcareAs of 2026-07-10 12:50
Why PSNL matters now
Personalis, Inc. (PSNL) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.01 with -4.37% on the session and $1.24B in market capitalization; recent performance reads 1-month +49.72% and YTD +32.41%.
The latest financial table shown here is Q1 2026, with revenue of $15.5M, net income of $-30.0M, and EPS of $-0.29. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.0%.
The latest indexable market news headline is "Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.00; recent insider activity includes EASTHAM KARIN filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.31
P/S
14.51
EV/EBITDA
-10.54
DCF Value
$1.04
FCF Yield
-9.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
13.7%
Operating Margin
-158.9%
Net Margin
-148.1%
ROE
-43.5%
ROA
-29.4%
ROIC
-34.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.5M | $-30.0M | $-0.29 |
| Q4 2025 | $17.3M | $-23.8M | $-0.26 |
| FY 2025 | $0.00 | $-81.3M | $-0.91 |
| Q3 2025 | $14.5M | $-21.7M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.00
Target (Median)
$11.00
Target Range
$9.00 - $13.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
2.28
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.